| Number of patients included /completers | 91/80 | 89/81 | – |
| Methotrexate (mg/week) 12 months | 20 (7/25) | 20 (7.5/20) | 0.33 |
| Triamcinolone (ml) cumulated 0–12 months | 7 (2/17.8) | 5.4 (1.8/16.6) | 0.084 |
| DAS28(CRP) 1 month | 3.4 (1.8–5.9) | 2.6 (1.7–5.1) | 0.003 |
| DAS28(CRP)≤2.6; 1 month | 29% | 48% | 0.010 |
| ΔDAS28 (CRP) 0–1 month | –1.9 (–0.3/–3.8) | –2.6 (–0.8/–4.7) | 0.0011 |
| DAS28(CRP) 12 months | 2.6 (1.7/4.7) | 2.0 (1.7/5.2) | 0.0088 |
| DAS28(CRP)≤2.6; 12 months | 49% | 74% | 0.0011 |
| CDAI ≤2,8; 12 months | 41% | 61% | 0.011 |
| SDAI ≤3.3; 12 months | 40% | 63% | 0.0028 |
| ACR/EULAR (28 joints) remission; 12 months | 31% | 48% | 0.0241 |
| ACR/EULAR (40 joints) remission; 12 months | 27% | 47% | 0.0098 |